clinical trial

AB0710 SHOULD I TAKE A TABLET OR GIVE MYSELF AN INJECTION? PATIENTS’ PERSPECTIVE ON THE CHOICE OF THE ADMINISTRATION OF METHOTREXATE (MTX) IN RHEUMATOID ARTHRITIS (RA)
A. Rafi, M. EL Morjani, Z. Baba, A. Mougui, I. El Bouchti

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1645; DOI: 10.1136/annrheumdis-2024-eular.5311
AB0549 THE EFFICACY AND SAFETY OF IGURATIMOD COMBINATION THERAPY WITH JAK INHIBITOR IN THE TREATMENT OF CsDMARDs-IR ACTIVE RHEUMATOID ARTHRITIS: A MULTICENTER, RANDOMIZED, PARALLEL-CONTROLLED CLINICAL STUDY FOR 24 WEEKS
Q. Shu, Q. Che, X. Qi, H. Lu, X. Zhang, L. Song

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1554; DOI: 10.1136/annrheumdis-2024-eular.4960
AB0551 HIGH-DOSE ORAL THIAMINE TREATMENT AGAINST CHRONIC FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS. A RANDOMISED CONTROLLED CROSS-OVER TRIAL
N. Stidsen, E. M. Hauge, P. Bager, T. B. Laurberg

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1555-1556; DOI: 10.1136/annrheumdis-2024-eular.5394
AB0567 PREVALENCE OF CONCOMITANT SARCOPENIA AND FRAILTY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY (PRESENT STUDY)
M. Tada, Y. Matsumoto, T. Koike, K. Mamoto, T. Nakamura, S. Anno, T. Iida, H. Goto, N. Hidaka

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1564; DOI: 10.1136/annrheumdis-2024-eular.654
AB0568 MILD ELEVATION OF CREATINE KINASE LEVELS BY JAK INHIBITORS INDEPENDENTLY OF CHANGE IN MUSCLE MASS: ANALYSIS OF DATA FROM A MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY
M. Tada, Y. Matsumoto, T. Koike, K. Mamoto, T. Nakamura, S. Anno, T. Iida, H. Goto, N. Hidaka

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1564-1565; DOI: 10.1136/annrheumdis-2024-eular.655
AB0569 PATIENT-REPORTED OUTCOMES (PROs), DISEASE ACTIVITY AND SAFETY IN 1,177 PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH FILGOTINIB FOR UP TO 18 MONTHS: INTERIM RESULTS FROM FILOSOPHY AND PARROTFISH
J. Avouac, G. R. Burmester, R. F. Caporali, T. P. A. Debray, F. De Leonardis, J. Galloway, N. Betteridge, K. Bevers, S. Romero-Yuste, M. Zignani, P. Verschueren

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1565-1566; DOI: 10.1136/annrheumdis-2024-eular.789
AB0638 DO HIGH RHEUMATOID FACTOR LEVELS IMPACT RESPONSE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH INADEQUATELY CONTROLLED RHEUMATOID ARTHRITIS? A POST HOC ANALYSIS OF THE PHASE 3B REALISTIC TRIAL
J. S. Smolen, T. Mikuls, J. Galloway, U. Müller-Ladner, J. R. Curtis, M. Hashimoto, T. Takeuchi, E. Choy, Y. Tanaka, C. Cara, B. Lauwerys, N. Tilt, B. Ufuktepe, P. C. Taylor

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1604-1605; DOI: 10.1136/annrheumdis-2024-eular.2883
AB0416 BIMEKIZUMAB IMPACT ON CARDIOVASCULAR INFLAMMATION MARKERS IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM PHASE 3 TRIALS
G. Kokolakis, R. B. Warren, R. G. Langley, B. Kirby, J. G. Krueger, K. Eyerich, L. Davis, O. Davies, N. Cross, D. Deherder, B. Strober

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1459; DOI: 10.1136/annrheumdis-2024-eular.2992
AB0420 PERFORMANCE OF THE 2021/2022 ASAS CRITERIA FOR DEFINING SACROILIITIS/SPONDYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS
X. Yan, I. T. Cheng, J. So, H. So, R. K. L. Lee, J. F. Griffith, L. S. Tam

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1461-1462; DOI: 10.1136/annrheumdis-2024-eular.4620
AB0426 LONGITUDINAL EVALUATION OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC DISEASE AND LEVELS OF SYSTEMIC INFLAMMATION ASSOCIATED WITH ELEVATED CARDIOVASCULAR RISK: POST HOC ANALYSIS OF 4 PHASE 3, RANDOMIZED, CONTROLLED STUDIES
J. F. Merola, A. Ogdie, A. Kavanaugh, E. Leibowitz, E. Rampakakis, F. Nantel, F. Lavie, K. Rowland, E. R. Soriano

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1466-1467; DOI: 10.1136/annrheumdis-2024-eular.103

Main menu

clinical trial

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

clinical trial

Pages